These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35677536)

  • 1. Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy.
    Wang Z; Li X; Wang X; Liu J; Wang L; Wei W; Duan X; Ding D
    J Immunol Res; 2022; 2022():6737241. PubMed ID: 35677536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of The Immune Subtype Among Muscle-invasive Bladder Cancer Patients by Multiple Datasets.
    Shinwari K; Chen Z; Liu G; Chen L; Bolkov MA; Tuzankina IA; Chereshnev VA
    Acta Med Indones; 2022 Jan; 54(1):62-71. PubMed ID: 35398827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
    Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X
    Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of the prognostic effect of costimulatory genes in bladder cancer.
    Su H; Liu Z; Zhang C; Deng Z; Su X; Wang Y; Liu W
    J Gene Med; 2024 Jan; 26(1):e3655. PubMed ID: 38282148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
    J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
    Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
    BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing bladder cancer management: development of a prognostic model and personalized therapy.
    Huang X; Du G; Yang Y; Su P; Chen S; Cai C; Huang T; Zeng Y; Tao Y; Tian D; Zhang N
    Front Immunol; 2024; 15():1430792. PubMed ID: 39104534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy.
    Wang H; Dai Y; Wu X; Hu B; Wang Z; Yan M
    Transl Cancer Res; 2022 Nov; 11(11):4089-4104. PubMed ID: 36523302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
    Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
    Cao R; Yuan L; Ma B; Wang G; Tian Y
    Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W; Zhu D; Wang C; Zhu Y
    Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
    Yan T; Zhou W; Li C
    Int Urol Nephrol; 2024 Nov; 56(11):3447-3462. PubMed ID: 38789872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
    Fan B; Zheng X; Wang Y; Hu X
    Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
    Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
    Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.